As global infectious disease threats escalate, GeoVax Labs Inc. (Nasdaq: GOVX) is drawing attention to the critical need for scalable domestic vaccine manufacturing infrastructure. The clinical-stage biotechnology company, based in Atlanta, Georgia, issued a statement on Monday highlighting how recent public health emergencies underscore the importance of diversified vaccine supply and U.S.-based production capabilities.
The World Health Organization’s declaration of a Public Health Emergency of International Concern (PHEIC) for the ongoing Ebola outbreak involving the Bundibugyo strain, coupled with the continued international spread of Clade I mpox and recent hantavirus concerns, has reinforced the dynamic nature of biodefense requirements. GeoVax believes these events validate its strategic focus on advancing GEO-MVA, its Modified Vaccinia Ankara (MVA)-based vaccine candidate for mpox and smallpox.
“These developments reinforce the importance of scalable and flexible vaccine preparedness infrastructure,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “GeoVax’s primary strategic focus remains the advancement of GEO-MVA, which we believe is well aligned with growing global emphasis on diversified vaccine supply, domestic manufacturing capability, and long-term biodefense preparedness.”
GeoVax is advancing GEO-MVA to support global orthopoxvirus preparedness and address the need for expanded vaccine supply. The company recently announced positive Scientific Advice from the European Medicines Agency supporting a Phase 3 immunobridging pathway toward potential regulatory approval. This pivotal trial is scheduled to initiate in the fourth quarter of 2026, with data results anticipated by mid-2027.
The company noted that the broader applicability of the MVA platform has been demonstrated in prior preclinical studies, including Ebola vaccine research where GeoVax’s MVA-based Ebola-Zaire candidate provided complete protection in non-human primate lethal-challenge studies following Ebola virus exposure.
GeoVax believes recent infectious disease developments further reinforce the strategic importance of diversified vaccine supply infrastructure, scalable domestic manufacturing capabilities, rapid-response vaccine platform technologies, and long-term investment in biodefense preparedness. The company emphasizes that preparedness infrastructure cannot remain reactive or narrowly focused on individual outbreak cycles.
“We believe the advancement of scalable domestic MVA-based manufacturing capability represents an important strategic objective for strengthening future biodefense readiness,” continued Mr. Dodd.
GeoVax’s priority program, GEO-MVA, is a next-generation MVA-based vaccine candidate in development for the prevention of mpox and smallpox infection. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026. The company also maintains a broader pipeline including Gedeptin®, a gene-directed enzyme prodrug therapy for oncology, and GEO-CM04S1, a next-generation COVID-19 vaccine candidate.
For more information, visit www.geovax.com.
This announcement comes as the WHO continues to monitor the Ebola outbreak and mpox spread, highlighting the ongoing need for robust vaccine development and manufacturing capacity.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is GeoVax Highlights Need for Domestic MVA Vaccine Infrastructure Amid Global Health Emergencies.